A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects

Trial Profile

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2017

At a glance

  • Drugs Botulinum toxin B (Primary)
  • Indications Sialorrhoea
  • Focus Registrational; Therapeutic Use
  • Acronyms MYSTICOL
  • Sponsors US WorldMeds
  • Most Recent Events

    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
    • 09 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 04 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top